Corvus (CRVS) stock's soquelitinib shows early promise in PTCL & atopic dermatitis, but a $1.24B valuation may be ahead of ...
Add Yahoo as a preferred source to see more of our stories on Google. With Gen Z street cred on one hand and brand-building prowess on the other, Maesa has teamed up with creators Brooklyn and Bailey ...
Aclaris is executing a two‑pronged pipeline strategy — a TSLP-targeted antibody platform and an ITK-focused oral kinase franchise — and expects multiple clinical readouts in the back half of 2026. The ...
T regulatory (Treg) cells promote immune tolerance and suppress inflammation 1,2. Unlike Treg cells that stably express the transcription factor Foxp3, type 1 regulatory T (Tr1) cells have no or ...
The last time I spoke about Corvus Pharmaceuticals, Inc. (CRVS), it was in a Seeking Alpha article entitled "Corvus Pharmaceuticals: Positive Phase 1 Soquelitinib Trial Data Brings 2025 Catalysts." ...
MyChesCo on MSN
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel ...
WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...
In its original avatar, ITK trained specialised coaches exclusively for the German set-up that made it a world power before the unification in the late '60s and early '70s. Germany's unprecedented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results